Current Trends: What to Expect in Funding Negotiations for a New Drug in Spain
In recent years, pharmaceutical funding trends in Spain have evolved due to increasing budget impact concerns aggravated by COVID-19. Experts Ana Mozetic, Laura Sánchez-Calero, Iván Bouza, and Elena Aldareguia analyzed funding decisions made by the Ministry of Health between 2019 and 2021 to help manufacturers understand what to expect.
In recent years, the budgetary impact caused by pharmaceutical expenditure has led to an evolution of trends in the funding of drugs in Spain.
This P&R brief focuses on the funding resolutions made at the national level for both innovative drugs accessing the market and available drugs extending their therapeutic indication. It analyzes the conditions granted together with the positive funding resolution (e.g., access restrictions, cost-containment measures, managed entry agreements in place).
